FDA 483 - Kovas Co., Ltd. - November 29, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Kovas Co., Ltd. in Paju-si, Gyeonggi-do, Korea, an OTC drug product manufacturer, was inspected by the FDA and found to have significant deficiencies. The inspection revealed inadequate controls over computer systems, unsound laboratory test methods, incomplete laboratory and batch production records, and failures in quality control unit responsibilities and equipment maintenance. These issues indicate a systemic lack of adherence to Good Manufacturing Practices, posing risks to the identity, strength, quality, and purity of drug products.
ID · 2f9ca0ae-4ebb-46e4-982a-60fa203185d6